Navigation Links
Abbott Honored With Scrip Award for Leadership in Corporate Social Responsibility

LONDON, Nov. 4, 2011 /PRNewswire/ -- Scrip, a leading global pharmaceutical and biotech news organisation, honored Abbott and its philanthropic foundation, the Abbott Fund, with a 2011 Scrip Award for Corporate Social Responsibility (CSR) at Scrip's seventh annual awards ceremony in London on Thursday evening.  The award was presented in recognition of the significant results achieved through a decade-long, public-private partnership with the Government of Tanzania to modernize the country's health system and address critical needs in the fight against HIV/AIDS and other life-long diseases.  

Unique Public-Private Partnership Highlights Social Innovation

"We're proud to receive this Scrip CSR Award on behalf of our Abbott Fund colleagues and the Government of Tanzania," said John B. Thomas, President, Abbott Fund.  "Over the past decade, we've combined our collective expertise and resources to fundamentally and sustainably upgrade the country's health care system.  This collaborative approach has supported nationwide improvements in addressing lifelong diseases, while also strengthening broader health care services provided to all Tanzanians."  

A key component of the programme is the involvement of highly specialised Abbott employee volunteers.  This includes lab technicians who have provided extensive training and mentoring for lab staff in Tanzania, as well as contributions from other experts working in construction, engineering, facility and equipment maintenance, health care management, information technology, security and waste management. To date, Abbott employees have contributed more than 10,000 hours of on-the-ground support for the initiative.  In addition, Abbott and the Abbott Fund have invested more than pounds Sterling 55 million (U.S. $90 million) in the Tanzania programme.

Decade-Long Partnership Provides Sustainable Improvements in Care

Over the past decade, Abbott, the Abbott Fund and the Government of Tanzania have modernised infrastructure, strengthened hospital management and systems, trained health workers, and expanded access to high-quality testing, treatment and care across the country.  Specific results include:

  • A 2007 government assessment found that nearly one in three people on HIV treatment in Tanzania received care at more than 90 facilities that benefited from the programme;
  • Modernised labs at all 23 regional-level hospitals, effectively upgrading lab services for the entire country;
  • Built a four-story outpatient center that sees hundreds of patients a day;
  • Constructed the country's first modern emergency center, providing life-saving services for 30,000 people last year;
  • Conducted more than 19,000 health care worker trainings; and
  • Provided support services for more than 150,000 children and families affected by HIV/AIDS.

Abbott Recognized With Scrip Awards in Recent Years

The Scrip Awards recognize excellence and achievement in the pharmaceutical and biotech industries. The CSR Award follows on other Scrip Awards Abbott has received in recent years; Scrip honored Abbott as the Company of the Year and Management Team of the Year in 2010, and Scrip recognized Abbott's Chairman and CEO Miles D. White as Executive of the Year in 2009.  

Additional Recognition for Abbott's Partnership in Tanzania

The Scrip CSR Award builds on other recognition for the partnership in Tanzania. In 2009, Abbott was honored with an International Community Service Award from the U.S. Chamber of Commerce's Business Civic Leadership Center (BCLC) for the Tanzania initiative.  Abbott also received the Global Business Coalition (GBC) National Action Award, one of the most prominent international honors for businesses working to advance global health.  

About Abbott's Approach to Citizenship

Global citizenship is an integral part of Abbott's mission to improve people's lives, focused on four key areas:  innovating for the future, enhancing access to health care, protecting patients and consumers, and safeguarding the environment.  Working in partnership with others, Abbott leverages its core business expertise and resources to create sustainable solutions in countries around the world.

Abbott was included on the prestigious Dow Jones Sustainability Indexes for the seventh consecutive year in 2011 in recognition of continued global leadership in economic, environmental and social performance.  Abbott also ranked No. 28 on Barron's magazine 2011 ranking of the world's most respected companies, and has been included on the 100 Best Corporate Citizens list compiled by Corporate Responsibility magazine for two consecutive years.

To learn more about Abbott's sustainability initiatives and to read or download the company's 2010 global citizenship report, please visit

About Abbott and the Abbott Fund

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs nearly 90,000 people and markets its products in more than 130 countries.  Abbott's news releases and other information are available on the company's website at

The Abbott Fund is a philanthropic foundation established by Abbott in 1951. The Abbott Fund's mission is to create healthier global communities by investing in creative ideas that promote science, expand access to health care and strengthen communities worldwide. For more information on the Abbott Fund, visit

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
(Date:11/24/2015)... 2015  Thanks to a donor with a personal ... Center,s Sister Diane Grassilli Center for Women,s Health now ... San Francisco . Fred ... with a gift of $617,320 that allowed the Center ... Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) mammography ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or ... today that the first patient has been enrolled in ... treatment for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States ... 1/2 clinical trial, ESSA intends to demonstrate the safety, ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... new market research report "Spine Biologics Market by Product Type ... Type (Anterior Cervical Discectomy and Fusion, Posterior Lumbar Interbody Fusion), ... by MarketsandMarkets, the global market was valued at $1.90 Billion ... 2020, at a CAGR of 4.4% during the forecast period ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon ... programs, launches new Wimbledon Athletics Facebook page to educate the public, ... unsuspected cardiac abnormalities. About 2,000 people under the age of 25 die from ...
(Date:11/25/2015)... ... 25, 2015 , ... Smiles by Stevens is pleased to announce ... wrinkling. While many patients are aware of the benefits of Botox® in the treatment ... those suffering with discomfort, soreness, and pain as a result of Jaw Tension, TMJ ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... decades of music, friendships, and learning in its 65th Anniversary Brillianteen Revue, scheduled ... 5-6. , For 65 years, Brillianteen has been a treasured tradition ...
(Date:11/25/2015)... D.C. (PRWEB) , ... November 25, 2015 , ... Today, ... fatalities on our nation’s roadways has dropped below 10,000 for the first time since ... 10,076 in 2013. , According to data released by the National Highway Traffic Safety ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... I found that regular bras were incredibly uncomfortable," said an inventor from Bronx, ... bra." , She developed the patent-pending RECOVERY BRA for added comfort and support. ...
Breaking Medicine News(10 mins):